The "Gastric Ulcers - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Gastric Ulcers - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Gastric Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Gastric Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Gastric Ulcers (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Companies Featured
- Boryung Pharmaceutical Co. Ltd.
- Daewoong Pharmaceutical Co. Ltd.
- Kukje Pharmaceutical Industry Co. Ltd.
- RaQualia Pharma Inc.
- XuanZhu Pharma Co. Ltd.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/49nlcm/gastric_ulcers?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180917005577/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Gastrointestinal
Drugs
